Certara, Inc. (HAM:700)
Germany · Delayed Price · Currency is EUR | Market Cap | 624.71M -61.6% |
| Revenue (ttm) | 364.05M +6.4% |
| Net Income | -13.10M |
| EPS | -0.09 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 11.35 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | n/a |
| Open | 3.870 |
| Previous Close | 3.928 |
| Day's Range | 3.870 - 3.881 |
| 52-Week Range | 3.744 - 8.446 |
| Beta | n/a |
| RSI | 26.89 |
| Earnings Date | May 11, 2026 |
About Certara
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scient... [Read more]
Financial Performance
In 2025, Certara's revenue was $418.84 million, an increase of 8.75% compared to the previous year's $385.15 million. Losses were -$1.60 million, -86.76% less than in 2024.
Financial numbers in USD Financial StatementsNews
Certara Transcript: RBC Capital Markets Global Healthcare Conference 2026
Leadership emphasized deep scientific expertise and a flexible business model, with AI integration and regulatory trends driving growth. Positive biotech funding and regulatory tailwinds support robust demand, while operational changes and cost actions aim to deliver double-digit growth and stable margins by 2026.
Certara to Participate in Upcoming Investor Conferences
RADNOR, Pa., May 18, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the followin...
Certara Transcript: AGM 2026
The meeting saw the re-election of three directors, ratification of the auditor, and approval of executive compensation. Shareholders participated virtually, and all proposals passed by majority vote. Voting results will be filed with the SEC.
Certara, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Certara, Inc. (NASDAQ: CERT). The investigation focuses on Certara's execut...
Certara price target lowered to $6 from $7 at BMO Capital
BMO Capital analyst Sean Dodge lowered the firm’s price target on Certara (CERT) to $6 from $7 and keeps a Market Perform rating on the shares. The company’s Q1 results…
Certara price target lowered to $8 from $10 at Craig-Hallum
Craig-Hallum lowered the firm’s price target on Certara (CERT) to $8 from $10 and keeps a Hold rating on the shares. The firm notes the company reported a soft quarter…
Certara price target lowered to $9 from $10 at Stephens
Stephens lowered the firm’s price target on Certara (CERT) to $9 from $10 and keeps an Overweight rating on the shares. The R&MW divestiture better aligns Certara around differentiated MIDD/biosimulat...
Certara price target lowered to $6 from $7 at Baird
Baird analyst Joe Vruwink lowered the firm’s price target on Certara (CERT) to $6 from $7 and keeps a Neutral rating on the shares.The firm updated its model following Q1…
Certara price target lowered to $10 from $11 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Certara (CERT) to $10 from $11 and keeps an Equal Weight rating on the shares. A rebound in software and “disappointment” in…
Certara trading halted, volatility trading pause
09:31 EDT Certara (CERT) trading halted, volatility trading pause
Certara price target lowered to $6.50 from $8 at Barclays
Barclays lowered the firm’s price target on Certara (CERT) to $6.50 from $8 and keeps an Equal Weight rating on the shares. The firm updated the company’s model post the…
Certara Q1 Earnings Call Highlights
Certara NASDAQ: CERT reported first-quarter 2026 revenue of $106.9 million, up 1% from the prior-year period, as stronger software performance offset softer services results and the company outlined a...
Certara Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 1% year-over-year, with strong software bookings and continued investment in AI and platform innovation. The company completed a major divestiture, reorganized around two growth areas, and reaffirmed full-year guidance, expecting stronger performance in the second half.
Certara Slides: Q1 2026
Certara has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 11, 2026.
Certara Earnings release: Q1 2026
Certara released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
Certara Quarterly report: Q1 2026
Certara has published its Q1 2026 quarterly earnings report on May 11, 2026.
Certara reports Q1 adjusted EPS 9c, consensus 11c
Reports Q1 revenue $106.9M, consensus $106.1M. “I am pleased with the progress we made in my first quarter at Certara (CERT),” said CEO Jon Resnick “We are taking decisive steps…
Certara sees FY26 adjusted EPS 35c-41c, consensus 45c
Sees FY26 revenue $395M-$405M, consensus $425.74M.
Certara Reports First Quarter 2026 Financial Results
Updates 2026 Guidance to reflect completed divestiture of Regulatory Writing and Medical Writing Business Updates 2026 Guidance to reflect completed divestiture of Regulatory Writing and Medical Writi...
Certara announces strategic partnership with Altasciences
Altasciencese and Certara (CERT) announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human tria...
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development
LAVAL, Québec & RADNOR, Pa.--(BUSINESS WIRE)-- #Altasciences--Altasciences, a fully integrated drug development solution company, and Certara (Nasdaq: CERT), a global leader in model-informed drug dev...
Certara to sell regulatory, medical writing business to Veristat for $135M
Certara (CERT) announced that it has entered into a definitive agreement to sell its regulatory and medical writing business to Veristat for a consideration of up to $135M. The transaction…
Certara Enters Definitive Agreement for the Sale of its Regulatory and Medical Writing Business to Veristat
Transaction sharpens focus on Model-Informed Drug Development (MIDD) and Clinical Intelligence Updated 2026 guidance to be provided upon transaction close RADNOR, Pa., April 22, 2026 (GLOBE NEWSWIRE)...
Veristat to Acquire Certara's Regulatory and Medical Writing Business
SOUTHBOROUGH, Mass.--(BUSINESS WIRE)-- #Biotech--Veristat (the “Company”), a science-first full-service CRO and consultancy that advances complex therapies through the drug development lifecycle to re...